Arch Biopartners Announces Dosing of First Patient in Turkey in Phase II Trial of LSALT peptide to Treat Complications from Covid-19

NEXT STORY
Clinical Microbiology Market Value Anticipated To Reach US$ 6.5 Bn By 2027: Impact of COVID-19 on the Market
PREV STORY
Replimune Reports Fiscal Second Quarter Financial Results and Provides Corporate Update
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

ContraFect Completes Enrollment in Phase 2 Clinical Trial Evaluating CF-301 (exebacase) in Patients with Staphylococcus Aureus Bacteremia

Company remains on track to announce top-line results in Q4 2018YONKERS, N.Y., Sept. 06, ...

author_avatar
NASDAQ Market News

Cidara Therapeutics Doses First Patient in Pivotal Phase 3 ReSPECT Trial of Rezafungin for Prevention of Invasive Fungal Disease in Patients Undergoing Allogeneic Blood and Marrow Transplantation

author_avatar
NASDAQ Market News

Stone Management Disposables (Nephrology and Urology Devices) – Global Market Analysis and Forecast Model (COVID-19 Market Impact)

author_avatar
NASDAQ Market News